Biogen looks to spin off hemophilia business to focus on neurology medicines
The US based biotechnology company plans to make hemophilia business a publicly traded independent company, so that each of the company will focus on their respective areas of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.